Compliance & Medical Disclaimer
This article is for informational and educational purposes only and does not constitute medical, legal, regulatory, or professional advice. The compounds discussed are research chemicals not approved for human consumption by the US FDA, European Medicines Agency (EMA), UK MHRA, Australian TGA, Health Canada, or any other major regulatory authority. They are sold strictly for laboratory research use. WolveStack does not employ medical staff, does not diagnose, treat, or prescribe, and makes no health claims under FTC, UK ASA, EU MDR/UCPD, or AU TGA standards. Always consult a licensed healthcare professional in your jurisdiction before considering any peptide protocol. This site contains affiliate links (FTC 2023 endorsement guidelines compliant); we may earn a commission on qualifying purchases at no additional cost to you. Some compounds discussed are on the WADA prohibited list — competitive athletes should verify current status with their governing body before any research use. Use of research chemicals may be illegal in your jurisdiction.
Editorial policy
Editorial review process: WolveStack Research Team — collective expertise in peptide pharmacology, regulatory science, and research literature analysis. We synthesize peer-reviewed studies, regulatory filings, and clinical trial data; we do not provide medical advice or treatment recommendations. Content is reviewed and updated as new evidence emerges.
Medical Disclaimer
This article is for informational and educational purposes only and does not constitute medical advice. The compounds discussed are research chemicals that are not FDA-approved for human use. Always consult a licensed healthcare professional before considering any peptide protocol. WolveStack has no medical staff and does not diagnose, treat, or prescribe. See our full disclaimer.
What Is Pinealon?
Pinealon is a synthetic tripeptide (Glu-Asp-Arg, or EDR) developed by Russian researchers as a bioregulator and geroprotector. It modulates gene expression in the pineal gland and promotes melatonin synthesis, supporting circadian rhythm regulation, neuroprotection, and anti-aging effects. Unlike many peptides that bind to specific receptors, Pinealon operates primarily through epigenetic mechanisms. Rather than binding a specific receptor and triggering a cascading signal, Pinealon appears to modulate gene expression within pineal gland cells—a process called epigenetic regulation. The pineal gland produces melatonin from serotonin via the enzyme arylalkylamine N-acetyltransferase (AANAT). Khavinson's work confirms that Pinealon increases pineal melatonin production in vivo and that the effect is organ-specific. The Khavinson model remains controversial in Western science—the mechanism is not fully understood, and the evidence base, while substantial in Russia, remains limited in peer-reviewed Western literature. Research suggests it may also exert neuroprotective effects and promote healthy aging processes.
Pinealon is a tripeptide comprising three amino acids: glutamic acid (Glu), aspartic acid (Asp), and arginine (Arg), abbreviated as EDR. It belongs to the Khavinson peptide family—a class of bioregulators developed by Russian immunologist Vladimir Khavinson based on the principle that short peptide chains derived from animal tissue secretions can regulate gene expression and cellular function.
Unlike many peptides that bind to specific receptors, Pinealon operates primarily through epigenetic mechanisms. It targets the pineal gland—a small neuroendocrine organ in the brain responsible for melatonin synthesis and circadian rhythm regulation—and enhances its capacity to produce melatonin and regulate sleep-wake cycles. Research suggests it may also exert neuroprotective effects and promote healthy aging processes.
Pinealon is approved for clinical use in Russia and some Eastern European countries, but remains unregulated in the United States and most Western nations. In the research peptide space, it is marketed for academic and preclinical study only.
How Does Pinealon Work? Mechanism of Action
Pinealon's mechanism differs fundamentally from receptor-based peptides. Rather than binding a specific receptor and triggering a cascading signal, Pinealon appears to modulate gene expression within pineal gland cells—a process called epigenetic regulation. Several pathways have been proposed:
Melatonin Amplification
The primary mechanism centers on pineal gland function. The pineal gland produces melatonin from serotonin via the enzyme arylalkylamine N-acetyltransferase (AANAT). Pinealon may upregulate genes responsible for AANAT expression or other rate-limiting steps in melatonin synthesis, increasing endogenous melatonin production. Higher melatonin levels support sleep consolidation, circadian phase alignment, and antioxidant defense.
Circadian Rhythm Regulation
Melatonin is the body's primary circadian timing hormone. By promoting melatonin synthesis, Pinealon indirectly strengthens circadian oscillations, improving sleep timing, sleep quality, and potentially metabolic regulation and hormone synchronization.
Neuroprotection & Anti-Aging
Melatonin and pineal function are also implicated in neuroinflammation control and cellular defense against oxidative stress. Enhanced melatonin production may reduce neuroinflammation, protect against neurodegeneration, and support mitochondrial health. Some research suggests pineal involution (age-related calcification) can be slowed by sustained melatonin production, supporting the "geroprotector" label.
Khavinson Bioregulator Model
The Khavinson paradigm proposes that tissue-derived peptides restore organ-specific gene expression when that organ has become dysfunctional or aged. Pinealon, derived from pineal tissue, may act as an "informational signal" that reminds pineal cells of their proper gene expression pattern, essentially resetting age-related decline in melatonin synthesis.
Key distinction: Pinealon is not a melatonin replacement—it does not supply exogenous melatonin. Instead, it appears to enhance the pineal gland's intrinsic capacity to synthesize and release melatonin endogenously.
What Does Research Show About Pinealon?
The body of evidence for Pinealon is primarily Russian and Eastern European. Most studies come from Khavinson's team at the Saint Petersburg Institute of Bioregulation and Gerontology, a leading center for peptide bioregulator research.
Preclinical Evidence
Animal models show that Pinealon administration increases pineal gland melatonin content and plasma melatonin levels, particularly in aging animals. Studies in rats and mice report improved sleep architecture, reduced age-related cognitive decline, enhanced immune function, and extended lifespan (in some models). The effects are consistent with a geroprotective profile—slowing rather than reversing aging markers.
Clinical Data (Limited)
Clinical data published in Russian-language journals report benefits in elderly patients including improved sleep quality, mood stabilization, reduced joint pain, and markers of improved immune function. A small open-label trial in geriatric patients reported improved sleep onset and sleep quality within 2-4 weeks. However, these studies are typically uncontrolled, open-label designs with small sample sizes and limited follow-up. Western peer-reviewed clinical trials are absent.
Mechanism Confirmation
Khavinson's work confirms that Pinealon increases pineal melatonin production in vivo and that the effect is organ-specific. It does not appear to act systemically; instead, it specifically targets pineal cells, supporting the bioregulator hypothesis. Whether the mechanism is gene-regulatory, receptor-mediated, or involving other cellular processes remains incompletely characterized.
Research status: Pinealon's evidence base is robust by Russian standards but limited in the Western scientific literature. Rigorous placebo-controlled trials in Western populations are lacking. Community reports and isolated clinical use support its safety profile, but efficacy remains largely inferred from mechanistic studies and small clinical series.
Pinealon Dosage & Administration
| Route | Dose | Frequency | Typical Cycle |
|---|---|---|---|
| Oral (tablet/capsule) | 10-30 mcg | Once daily | 10 days on, 5-10 days off |
| Sublingual (tablet) | 10-30 mcg | Once daily | 10 days on, 5-10 days off |
| Nasal spray | 10-20 mcg per spray | 1-2 sprays daily | 10 days on, 5-10 days off |
| Subcutaneous injection | 10-20 mcg | Once daily | 5-10 day cycles |
Typical Dosing Protocol
Standard Cycle: 10-20 mcg once daily for 10 days, followed by a 5-10 day break. Repeat for 2-3 cycles (roughly 1-2 months total), then reassess or take a longer break (2-4 weeks).
Administration Timing: Oral/sublingual forms are typically taken in the morning, though some prefer evening to capitalize on natural melatonin production times. Nasal spray and injections can be taken any time, though morning or evening are most common.
Half-life: Estimated 18-24 hours, though exact pharmacokinetics are not well-documented in the literature.
Practical Administration Notes
If using injectable Pinealon (provided as lyophilized powder), reconstitution is typically done with sterile saline or bacteriostatic water. Use a ratio of roughly 1 mL per 10 mg of powder (though exact recommendations vary by manufacturer). Once reconstituted, store in the refrigerator (2-8°C) and use within 2-4 weeks.
Oral tablets/capsules and sublingual formulations are stable at room temperature and require no preparation. Nasal spray formulations are pre-made and also stable at room temperature.
Khavinson Bioregulator Research Context
To understand Pinealon, context on the broader Khavinson bioregulator research program is useful. Vladimir Khavinson, a Russian immunologist, pioneered the theory that synthetic short peptides derived from healthy animal tissues can restore organ-specific gene expression in aging or stressed tissues. The concept is that as tissues age, their gene expression pattern drifts from optimal, and reintroducing the "normal" peptide signal can partially restore function.
Under this paradigm, Khavinson developed peptides targeting multiple organs: Epithalon (pineal/telomerase), Thymalin (thymus/immunity), Ventfort (blood vessels), Cartrogen (cartilage), and others. Pinealon specifically targets the pineal gland.
The Khavinson model remains controversial in Western science—the mechanism is not fully understood, and the evidence base, while substantial in Russia, remains limited in peer-reviewed Western literature. However, the safety record is robust, and community interest in bioregulators has grown as aging research has expanded.
Pinealon vs. Other Sleep & Circadian Peptides
Pinealon vs. DSIP (Delta Sleep Inducing Peptide)
DSIP is another sleep-promoting peptide that directly induces slow-wave sleep in animal models. Unlike Pinealon, DSIP appears to act centrally (in the brain) to enhance deep sleep architecture. Pinealon works via melatonin enhancement and circadian regulation, not direct sleep induction. DSIP may produce faster subjective sleep benefits, while Pinealon may support longer-term circadian health and anti-aging benefits. Many users combine them.
Pinealon vs. Epithalon
Epithalon is another Khavinson peptide, also targeting the pineal gland but with a broader focus on telomerase activation and cellular senescence. Both are bioregulators; Pinealon is more sleep/melatonin-focused while Epithalon is more broadly anti-aging. Some users dose both in sequence.
Pinealon vs. Exogenous Melatonin
Pinealon is not a melatonin supplement—it does not supply exogenous melatonin. Instead, it enhances endogenous melatonin synthesis. Melatonin supplements (typically 1-10 mg) provide immediate, predictable melatonin levels and are often more effective for acute sleep problems. Pinealon may be better suited for long-term circadian health and anti-aging support, with a slower onset but potentially more sustainable benefits. The two can be combined.
Research perspective: Pinealon's advantage over direct sleep aids is its potential to strengthen endogenous circadian regulation rather than temporarily masking sleep deficiency. This aligns with emerging chronobiology research emphasizing circadian health as foundational to aging and disease prevention.
Side Effects & Safety
Common Side Effects
Minimal and generally well-tolerated. Most users report no side effects. Reported side effects, when they occur, are minor:
- Injection site reactions (redness, mild soreness) if using subcutaneous form — typically resolve within 24 hours.
- Mild headache in the first 1-2 days of use — usually transient.
- Muscle aches or mild malaise, particularly in older users — rare and typically mild.
- Transient lightheadedness or dizziness — uncommon and resolves quickly.
Serious Adverse Events
No serious adverse events have been reported in the literature. Pinealon has a very clean safety profile in clinical use in Russia.
Contraindications & Cautions
No absolute contraindications are documented. However, use in pregnant or breastfeeding women has not been studied; these populations should avoid use pending further research. Similarly, those with active pineal gland pathology (pineal cysts, tumors) should consult a healthcare provider before use.
Long-Term Safety
The longest published studies span 2-3 months of intermittent use. Long-term safety data (years of continuous use) are lacking in Western literature, though Russian clinical experience has not raised safety concerns. The cycling protocol (10 days on, 5-10 days off) is a reasonable precaution pending longer studies.
Pinealon FAQ
Melatonin supplements provide exogenous (external) melatonin—you ingest melatonin molecules directly. Pinealon does not supply melatonin; instead, it stimulates the pineal gland to produce melatonin endogenously (from within your body). Melatonin works faster but is temporary. Pinealon works more slowly but may support more lasting circadian improvements and anti-aging benefits by restoring the pineal gland's function.
Subjective effects typically appear in 2-4 weeks of consistent use. Improved sleep quality and mood may be noticed first. Circadian rhythm improvements and anti-aging benefits likely take longer (weeks to months) to become apparent. Effects are often subtle—users typically report gradual improvements in sleep quality, morning alertness, and daytime energy rather than dramatic overnight changes.
Pinealon is approved for clinical use in Russia and some Eastern European countries. In the United States, it is not FDA-approved and is available only through research peptide suppliers for academic and laboratory use. Its legal status varies by country. Users should verify local regulations before purchasing. It is not a controlled substance but remains unregulated in most Western jurisdictions.
Yes, Pinealon combines safely with most sleep-supporting supplements. Many users combine it with melatonin (which works through a different mechanism), magnesium, valerian, or GABA. Some combine Pinealon with other Khavinson peptides (like Epithalon). However, combining multiple bioactive compounds always carries some risk; start cautiously and monitor for unexpected effects. Consult a healthcare provider if you are on prescription sleep medications.
There is no strong evidence for optimal timing, though several patterns are used. Some take it in the morning to support daytime circadian alignment. Others take it in the evening (1-2 hours before sleep) to support nighttime melatonin synthesis. The most important factor is consistency—daily, regular dosing appears more important than the exact time. Experiment and note what time correlates with the best sleep quality for you.
Theoretically, yes. Pinealon's mechanism (enhancing melatonin synthesis and circadian resilience) may help night shift workers and those with irregular schedules better adapt to non-standard sleep-wake cycles. However, no specific trials in shift workers exist. Anecdotal reports suggest combining Pinealon with strategic light exposure and consistent meal timing may improve adaptation. Anyone with a severely disrupted circadian rhythm should consult a sleep specialist.